MedDataX Logo

ATEM (Alvesco Non-interventional Study)

NCT ID: NCT01147224

Last Updated: 2016-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

NCT02479412

Asthma Efficacy Safety
COMPLETED PHASE2

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

NCT05251259

Asthma
COMPLETED PHASE2

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

NCT06020014

Asthma
COMPLETED PHASE2

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.

NCT01704495

Asthma
COMPLETED PHASE2

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621

Asthma
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ATEM

A prospective one-arm non-interventional study with asthma patients treated with Alvesco.

Alvesco

Intervention Type DRUG

This is an observational study. Therefore, the physician decides about dosage according to individual needs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alvesco

This is an observational study. Therefore, the physician decides about dosage according to individual needs.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ciclesonide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asthma with or without allergic components

Exclusion Criteria

* Hypersensitive to compounds of Alvesco
* Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca AstraZeneca

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nycomed Pharma GmbH

Amstetten, , Austria

Site Status

Nycomed Pharma GmbH

Baden, , Austria

Site Status

Nycomed Pharma GmbH

Bludenz, , Austria

Site Status

Nycomed Pharma GmbH

Böhlerwerk, , Austria

Site Status

Nycomed Pharma GmbH

Braunau am Inn, , Austria

Site Status

Nycomed Pharma GmbH

Bregenz, , Austria

Site Status

Nycomed Pharma GmbH

Dornbirn, , Austria

Site Status

Nycomed Pharma GmbH

Enns, , Austria

Site Status

Nycomed Pharma GmbH

Feldbach, , Austria

Site Status

Nycomed Pharma GmbH

Feldkirch, , Austria

Site Status

Nycomed Pharma GmbH

Furth, , Austria

Site Status

Nycomed Pharma GmbH

Gföhl, , Austria

Site Status

Nycomed Pharma GmbH

Gr. Siegharts, , Austria

Site Status

Nycomed Pharma GmbH

Graz, , Austria

Site Status

Nycomed Pharma GmbH

Graz, , Austria

Site Status

Nycomed Pharma GmbH

Graz, , Austria

Site Status

Nycomed Pharma GmbH

Graz, , Austria

Site Status

Nycomed Pharma GmbH

Graz-Gösting, , Austria

Site Status

Nycomed Pharma GmbH

Groß-Gerungs, , Austria

Site Status

Nycomed Pharma GmbH

Gunskirchen, , Austria

Site Status

Nycomed Pharma GmbH

Güssing, , Austria

Site Status

Nycomed Pharma GmbH

Haag, , Austria

Site Status

Nycomed Pharma GmbH

Hall in Tirol, , Austria

Site Status

Nycomed Pharma GmbH

Hallein, , Austria

Site Status

Nycomed Pharma GmbH

Hartberg, , Austria

Site Status

Nycomed Pharma GmbH

Herzogenburg, , Austria

Site Status

Nycomed Pharma GmbH

Innsbruck, , Austria

Site Status

Nycomed Pharma GmbH

Judenburg, , Austria

Site Status

Nycomed Pharma GmbH

Kaltenbach, , Austria

Site Status

Nycomed Pharma GmbH

Kirchdorf and Der Krems, , Austria

Site Status

Nycomed Pharma GmbH

Kitzbühel, , Austria

Site Status

Nycomed Pharma GmbH

Klein-Pöchlam, , Austria

Site Status

Nycomed Pharma GmbH

Landeck, , Austria

Site Status

Nycomed Pharma GmbH

Leibnitz, Styria, , Austria

Site Status

Nycomed Pharma GmbH

Lenzing, , Austria

Site Status

Nycomed Pharma GmbH

Linz, , Austria

Site Status

Nycomed Pharma GmbH

Linz, , Austria

Site Status

Nycomed Pharma GmbH

Linz, , Austria

Site Status

Nycomed Pharma GmbH

Litschau, , Austria

Site Status

Nycomed Pharma GmbH

Mank, , Austria

Site Status

Nycomed Pharma GmbH

Melk, , Austria

Site Status

Nycomed Pharma GmbH

Mittersill, , Austria

Site Status

Nycomed Pharma GmbH

Mödling, , Austria

Site Status

Nycomed Pharma GmbH

Mühldorf, , Austria

Site Status

Nycomed Pharma GmbH

Münster, , Austria

Site Status

Nycomed Pharma GmbH

Neumarkt am Wallersee, , Austria

Site Status

Nycomed Pharma GmbH

Niederkreuzstetten, , Austria

Site Status

Nycomed Pharma GmbH

Pasching, , Austria

Site Status

Nycomed Pharma GmbH

Pinkafeld, , Austria

Site Status

Nycomed Pharma GmbH

Pucking, , Austria

Site Status

Nycomed Pharma GmbH

Saint Johann I. Pg., , Austria

Site Status

Nycomed Pharma GmbH

Salzburg, , Austria

Site Status

Nycomed Pharma GmbH

Sankt Pölten, , Austria

Site Status

Nycomed Pharma GmbH

Schlüsslberg, , Austria

Site Status

Nycomed Pharma GmbH

Schörfling, , Austria

Site Status

Nycomed Pharma GmbH

Schwanenstadt, , Austria

Site Status

Nycomed Pharma GmbH

St.Georgen i.A., , Austria

Site Status

Nycomed Pharma GmbH

Steyr, , Austria

Site Status

Nycomed Pharma GmbH

Strallegg, , Austria

Site Status

Nycomed Pharma GmbH

Sulz, , Austria

Site Status

Nycomed Pharma GmbH

Thalheim bei Wels, , Austria

Site Status

Nycomed Pharma GmbH

Traisen, , Austria

Site Status

Nycomed Pharma GmbH

Traismauer, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Vienna, , Austria

Site Status

Nycomed Pharma GmbH

Voitsberg, , Austria

Site Status

Nycomed Pharma GmbH

Waidhofen/Thaya, , Austria

Site Status

Nycomed Pharma GmbH

Weitra, , Austria

Site Status

Nycomed Pharma GmbH

Wiener Neustadt, , Austria

Site Status

Nycomed Pharma GmbH

Wilhelmsburg, , Austria

Site Status

Nycomed Pharma GmbH

Ysper, , Austria

Site Status

Nycomed Pharma GmbH

Zwettl Stadt, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CL-9709-401-DE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
NCT00603746 COMPLETED PHASE2
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
NCT00736489 COMPLETED PHASE2
Short Treatment with Omalizumab for Severe Asthma
NCT04763447 RECRUITING PHASE4
A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449
NCT03766399 COMPLETED PHASE1
A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects
NCT03622112 COMPLETED PHASE2
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
NCT00535431 COMPLETED PHASE2
Roflumilast Plus Montelukast in Adults With Severe Asthma
NCT01765192 COMPLETED PHASE2
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794 COMPLETED PHASE2
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
NCT05288504 COMPLETED PHASE2
Asthma Severity in Women: The Influence of Training and Menopause
NCT03747211 TERMINATED NA
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419 ACTIVE_NOT_RECRUITING PHASE2
Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia
NCT01114906 COMPLETED
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
NCT00442351 TERMINATED PHASE4
Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis
NCT02953106 TERMINATED PHASE4
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
NCT01085474 COMPLETED
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
NCT01147744 COMPLETED PHASE2
Study Evaluating Etanercept in Moderate to Severe Asthma
NCT00141791 COMPLETED PHASE2
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
NCT07214753 RECRUITING
Study in Patients With Asthma
NCT00215358 COMPLETED PHASE2
Study in Patients With Asthma
NCT00215410 COMPLETED PHASE2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
NCT00603278 COMPLETED PHASE2
Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT04643158 TERMINATED PHASE2
Repeat Dose Safety Study for Compound to Treat Asthma
NCT01202214 COMPLETED PHASE1
Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®
NCT01484210 COMPLETED PHASE3
AZMATICS: AZithroMycin/Asthma Trial In Community Settings
NCT00266851 COMPLETED PHASE3